MetaSystems proudly announces the opening of our first subsidiary in the Southern hemisphere. The new office is located in Buenos Aires, Argentina and bears the name MetaSystems Latinoamérica SAS (MetaSystems LatAm). The foundation has been the response to the growing demand on technical knowledge and 'know how' experienced in the last years all over the Latin American territories. MetaSystems LatAm takes care for the organization of sales, support, and customer relation activities in all countries in Latin America. It will manage distributor companies and contacts in the region, and it will facilitate communication between end-users, distributors and headquarters in Germany.
XL ABL2 BA
Break Apart Probe
- Order Number
- Package Size
- 100 µl
Acute lymphoblastic leukemia (ALL) is a rare disease with approximately 1:100.000 new diagnoses per year. Around 3-5% of pediatric ALL and 25% of adult ALL are characterized by t(9;22), resulting in the BCR-ABL1 fusion gene, a constitutively active tyrosine kinase. Furthermore, BCR-ABL1 is genetically characterizing chronic myelogenous leukemia. Tyrosine kinase inhibitor treatment of BCR-ABL1-positive cases, which initially have a poor prognosis, dramatically improve the outcome. A novel high risk subtype called BCR-ABL1-like ALL or Philadelphia-like ALL was discovered based on similar gene expression profiles to BCR-ABL1-positive ALL and is characterized by aberrations, resulting in activation of tyrosine kinase signaling pathways. Prominent genes in the JAK/STAT activating group are CRLF2, EPOR and JAK2, members of the ABL-class fusions are ABL1, ABL2, CSF1R and PDGFRB. ´The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia´ specifies B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like as a provisional entity.
The ABL2 gene has been initially identified as a novel fusion partner of ETV6. ABL2 belongs to the Abelson family of non-receptor tyrosine kinases and is highly similar to ABL1. t(1;12)(q25;p13) results in a chimeric ETV6-ABL2 protein with a constitutive active tyrosine kinase.
- Acute Lymphoblastic Leukemia (ALL)
XL ABL2 BA hybridized to HT-93 cells carrying t(1;12) and t(15;17), one interphase is shown. The separation of one colocalization/fusion signal indicates a split of the orange and green labled probes flanking the ABL2 breakpoint region. The remaining copy of ABL2 contributes one colocalization/fusion signal. The additional orange signal was interpreted to be localized on a derivative chromosome 4 representing a duplication of parts of the q-arm of the derivative chromosome 1.
Two green-orange colocalization/fusion signals (2GO).
Aberrant Cell (typical results):
One green-orange colocalization/fusion signal (1GO), one separate green (1G) and orange (1O) signal each resulting from a chromosome break in the respective locus.
- Iijima et al (2000) Blood 95:2126-2131
- Arber et al (2016) Blood 127:2391-2405
- Tasian et al (2017) Blood 130:2064-2072